“Penny Pricing” Guidance Document On Hold Until 340B Office Gets Funding

A long-promised official policy on "penny pricing" for drugs sold to 340B entities is on hold until Congress appropriates funding for the Health Resources and Services Administration's Office of Pharmacy Affairs. Until then, drug manufacturers will need to work on a case-by-case basis with OPA to resolve any pricing issues